Medpace Stake Inc (MEDP) CEO Sold $535,849.20 in Shares

Medpace Stake Inc (MEDP) CEO Sold $535,849.20 in Shares

Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 8,760 shares of the stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $61.17, for a total value of $535,849.20. Following the transaction, the chief executive officer now owns 603,702 shares of the company’s stock, valued at approximately $36,928,451.34. The transaction was disclosed in a filing with the SEC, which is available at this link.

NASDAQ:MEDP traded down $0.62 during mid-day trading on Friday, reaching $64.07. The stock had a trading volume of 852,572 shares, compared to its average volume of 577,219. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of 42.15, a price-to-earnings-growth ratio of 1.36 and a beta of 1.76. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.66 and a quick ratio of 0.66. Medpace Holdings Inc has a 12 month low of $31.75 and a 12 month high of $69.71.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in Medpace by 82.2% in the fourth quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock valued at $220,103,000 after buying an additional 1,876,296 shares in the last quarter. New York State Common Retirement Fund boosted its position in Medpace by 14.1% in the fourth quarter. New York State Common Retirement Fund now owns 38,938 shares of the company’s stock valued at $2,061,000 after buying an additional 4,802 shares in the last quarter. 361 Capital LLC boosted its position in Medpace by 71.2% in the fourth quarter. 361 Capital LLC now owns 46,837 shares of the company’s stock valued at $2,479,000 after buying an additional 19,484 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Medpace by 595.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 285,664 shares of the company’s stock valued at $15,121,000 after buying an additional 244,595 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in Medpace by 13.9% in the fourth quarter. Prudential Financial Inc. now owns 432,071 shares of the company’s stock valued at $22,869,000 after buying an additional 52,761 shares in the last quarter. Hedge funds and other institutional investors own 72.44% of the company’s stock.

MEDP has been the subject of several recent analyst reports. BidaskClub downgraded shares of Medpace from a “strong-buy” rating to a “buy” rating in a research note on Friday. ValuEngine upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, January 10th. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday, January 9th. Finally, SunTrust Banks upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a research note on Wednesday, October 31st. They noted that the move was a valuation call. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $44.43.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Recommended Story: What is a bull market?

Related posts

Leave a Comment